Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Napabucasin + Standard Chemotherapy in Advanced GI Cancer
NCT02024607Phase 2Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Jan 2014
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of napabucasin in gastrointestinal cancer, colorectal cancer (CRC), hepatocellular carcinoma (HCC), pancreatic adenocarcinoma (PDAC), cholangiocarcinoma (CCA), sponsored by Sumitomo Pharma America. Started Jan 2014; status: completed.
02
Drugs
napabucasin
03
Conditions
gastrointestinal cancercolorectal cancer (CRC)hepatocellular carcinoma (HCC)pancreatic adenocarcinoma (PDAC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT02024607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02024607.